Innoviva, Inc. (INVA): Gross Profit
$307.67M
Year ended 2025-12-31
$317.65M
Trailing 12 months to 2026-06-30
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $307.67M | +3.9% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $296.21M | +20.4% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $246.04M | n/a | 2026-02-25, From 2023-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Innoviva, Inc. (INVA) | 2025-12-31 | $307.67M | +3.9% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $367.78M | +29.9% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $261.98M | +18.7% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $335.38M | +127.5% |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $266.66M | +6.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $347.72M | +7.1% |
| MannKind Corp (MNKD) | 2025-12-31 | $322.17M | +20.2% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $275.75M | +584.5% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $212.16M | -24.6% |
Compare INVA, ARDX, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗